SCHEMBL20199448

SCHEMBL20199448

c1ccc(-c2cc(-c3ccccc3)nc(-n3c4ccccc4c4cc5c(cc43)C3(c4ccccc4-c4ccccc43)c3ccccc3C53c4ccccc4-c4ccccc43)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
NPSR1 Q6W5P4 3/20 0.34
AGTR1 P30556 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
LMNA P02545 1/20 0.34
MAPK10 P53779 1/20 0.34
L3MBTL1 Q9Y468 4/20 0.33
MAPK1 P28482 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20199475 0.99 MAPT (0.35) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL20199502 0.94 MAPT (0.34) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL20199790 0.94 MAPT (0.34) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL25121523 0.93 MAPT (0.34) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL802703 0.93 MAPT (0.34) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL25121554 0.91 MAPT (0.33) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL24078426 0.91 MAPT (0.33) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL20199451 0.89 L3MBTL1 (0.31) MAPTMEN1KMT2ALMNAL3MBTL1
SCHEMBL25121717 0.89 MAPT (0.34) MAPTSMN1; SMN2NPSR1AGTR1CYP1A2
SCHEMBL20199472 0.88 L3MBTL1 (0.32) MAPTSMN1; SMN2MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001752-B2 Double spiro organic compound and organic electronic element comprising same LG CHEM, LTD. (KR) 2021-05-11 US disclosed
EP-3305764-B1 DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME LG CHEMICAL LTD (KR) 2019-09-25 EP disclosed
US-20180148640-A1 DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-05-31 US disclosed
US-20180148640-A1 DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11001752-B2 Double spiro organic compound and organic electronic element comprising same DCX, TERT, TELO2 MAPT 1276/4885SMN1; SMN2 121/4885NPSR1 4755/4885
US-20180148640-A1 DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME DCX, TERT, TELO2 MAPT 1276/4885SMN1; SMN2 121/4885NPSR1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.